Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurocritical Care
Published in: Neurocritical Care 1/2022

25-03-2022 | Guillain-Barré Syndrome | Original work

Risk Factors for Mechanical Ventilation in Patients with Guillain–Barré Syndrome

Authors: Yanwei Cheng, Kangding Liu, Chunrong Li, Weiwei Zhang, Xiujuan Wu, Shaokuan Fang

Published in: Neurocritical Care | Issue 1/2022

Login to get access

Abstract

Background

Respiratory support is required in 20–30% of patients with Guillain–Barré syndrome (GBS). We investigated clinical and biological risk factors for mechanical ventilation (MV) in northeast China through a retrospective GBS study. The Erasmus GBS Respiratory Insufficiency Score (EGRIS) is a prognostic model for MV in patients with GBS, and its usefulness has been validated in several countries but not in China. Therefore, we intended to validate the EGRIS model in our GBS cohort.

Methods

A total of 252 patients with GBS were included in this study from January 2013 to October 2017. Risk factors for MV were identified via multivariate logistic regression analysis. The prognostic value of the EGRIS was validated via receiver operating characteristic curve analysis.

Results

Thirty-one patients (12.3%) required MV (mean age 54.19 years), with a majority being male (77.4%). The risk factors for MV were male sex [odds ratio (OR) 3.720, 95% confidence interval (CI) 1.155–11.985, p < 0.05], shorter interval from onset to admission (OR 0.830, 95% CI 0.711–0.970, p < 0.05), lower Medical Research Council sum score at admission (OR 0.942, 95% CI 0.911–0.973, p < 0.001), neutrophil-to-lymphocyte ratio at admission (OR 1.174, 95% CI 1.049–1.315, p < 0.01), and cranial nerve deficit (OR 3.805, 95% CI 1.373–10.541, p < 0.05). The EGRIS had a good predictive ability for MV (area under the receiver operating curve 0.861) in patients with GBS, and a high EGRIS was a predictor for MV (OR 8.778, 95% CI 3.432–22.448, p < 0.001). However, there was no significant difference in ganglioside administration between ventilated and nonventilated patients.

Conclusions

An elevated neutrophil-to-lymphocyte ratio at admission and a high EGRIS could serve as predictors for MV in our GBS cohort.
Literature
1.
Wu X, Wu W, Wang Z, et al. More severe manifestations and poorer short-term prognosis of ganglioside-associated Guillain–Barré syndrome in Northeast China. PLoS ONE. 2014;9(8):e104074.CrossRefPubMedPubMedCentral
2.
Wakerley BR, Yuki N. Infectious and noninfectious triggers in Guillain–Barre syndrome. Expert Rev Clin Immunol. 2013;9(7):627–39.CrossRefPubMed
3.
4.
Willison HJ, Jacobs BC, van Doorn PA. Guillain–Barré syndrome. The Lancet. 2016;388(10045):717–27.CrossRef
5.
Islam Z, Papri N, Ara G, et al. Risk factors for respiratory failure in Guillain-Barre syndrome in Bangladesh: a prospective study. Ann Clin Transl Neurol. 2019;6(2):324–32.CrossRefPubMedPubMedCentral
6.
Green C, Baker T, Subramaniam A. Predictors of respiratory failure in patients with Guillain-Barre syndrome: a systematic review and meta-analysis. Med J Aust. 2018;208(4):181–8.CrossRefPubMed
7.
Durand M-C, Porcher R, Orlikowski D, et al. Clinical and electrophysiological predictors of respiratory failure in Guillain–Barré syndrome: a prospective study. Lancet Neurol. 2006;5(12):1021–8.CrossRefPubMed
8.
Wu X, Li C, Zhang B, et al. Predictors for mechanical ventilation and short-term prognosis in patients with Guillain–Barre syndrome. Crit Care. 2015;19:310.CrossRefPubMedPubMedCentral
9.
Haifeng L. Anti-GQ1b antibody as a factor predictive of mechanical ventilation in Guillain–Barre syndrome. Neurology. 2004;63(10):1985.CrossRefPubMed
10.
Durand MC, Lofaso F, Lefaucheur JP, et al. Electrophysiology to predict mechanical ventilation in Guillain–Barré syndrome. Eur J Neurol. 2003;10(1):39–44.CrossRefPubMed
11.
Kannan Kanikannan MA, Durga P, Venigalla NK, et al. Simple bedside predictors of mechanical ventilation in patients with Guillain–Barre syndrome. J Crit Care. 2014;29(2):219–23.CrossRefPubMed
12.
Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain–Barre syndrome. Ann Neurol. 2010;67(6):781–7.PubMed
13.
Yamagishi Y, Suzuki H, Sonoo M, et al. Markers for Guillain–Barre syndrome with poor prognosis: a multi-center study. J Peripher Nerv Syst. 2017;22(4):433–9.CrossRefPubMed
14.
Tan CY, Razali SNO, Goh KJ, Shahrizaila N. The utility of Guillain–Barre syndrome prognostic models in Malaysian patients. J Peripher Nerv Syst. 2019;24(2):168–73.CrossRefPubMed
15.
Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain–Barré syndrome. Ann Neurol. 1990;27(Suppl):S21–4.CrossRefPubMed
16.
17.
Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978;2(8093):750–3.CrossRefPubMed
18.
Kleyweg RP, van der Meché FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain–Barré syndrome. Muscle Nerve. 1991;14(11):1103–9.CrossRefPubMed
19.
Sharshar T, Chevret S, Bourdain F, Raphaël JC. Early predictors of mechanical ventilation in Guillain–Barré syndrome. Crit Care Med. 2003;31(1):278–83.CrossRefPubMed
20.
Ning P, Yang B, Yang X, et al. A nomogram to predict mechanical ventilation in Guillain–Barre syndrome patients. Acta Neurol Scand. 2020;142(5):466–74.CrossRefPubMed
21.
Paul BS, Bhatia R, Prasad K, et al. Clinical predictors of mechanical ventilation in Guillain–Barre syndrome. Neurol India. 2012;60(2):150–3.CrossRefPubMed
22.
Omichi K, Cloyd JM, Yamashita S, et al. Neutrophil-to-lymphocyte ratio predicts prognosis after neoadjuvant chemotherapy and resection of intrahepatic cholangiocarcinoma. Surgery. 2017;162(4):752–65.CrossRefPubMed
23.
Qun S, Tang Y, Sun J, et al. Neutrophil-to-lymphocyte ratio predicts 3-month outcome of acute ischemic stroke. Neurotox Res. 2017;31(3):444–52.CrossRefPubMed
24.
Diniz LR, de Lima SG, de Amorim Garcia JM, de Oliveira Diniz KL. Neutrophil to lymphocyte ratio as a prognostic predictor in older people with acute coronary syndrome. Angiology. 2019;70(3):264–71.CrossRefPubMed
25.
Ozdemir HH. Analysis of the albumin level, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio in Guillain–Barre syndrome. Arq Neuropsiquiatr. 2016;74(9):718–22.CrossRefPubMed
26.
Huang Y, Ying Z, Quan W, et al. The clinical significance of neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio in Guillain–Barre syndrome. Int J Neurosci. 2018;128(8):729–35.CrossRefPubMed
27.
Tunc A. Early predictors of functional disability in Guillain–Barre syndrome. Acta Neurol Belg. 2019;119(4):555–9.CrossRefPubMed
28.
Huner EA, Dai AI, Demiryurek AT. Association of neutrophil/lymphocyte ratio with intravenous immunoglobulin treatment in children with Guillain–Barre syndrome. J Child Neurol. 2018;33(2):164–7.CrossRefPubMed
29.
Capone M, Giannarelli D, Mallardo D, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018;6(1):74.CrossRefPubMedPubMedCentral
30.
Shang P, Zhu M, Baker M, et al. Mechanical ventilation in Guillain–Barre syndrome. Expert Rev Clin Immunol. 2020;16(11):1053–64.CrossRefPubMed
31.
Liu S, Xiao Z, Lou M, et al. Guillain–Barré syndrome in southern China: retrospective analysis of hospitalised patients from 14 provinces in the area south of the Huaihe River. J Neurol Neurosurg Psychiatr. 2018;89(6):618–26.CrossRef
32.
Kalita J, Ranjan A, Misra UK. Outcome of Guillain–Barre syndrome patients with respiratory paralysis. QJM. 2016;109(5):319–23.CrossRefPubMed
33.
Walgaard C, Lingsma HF, van Doorn PA, et al. Tracheostomy or not: prediction of prolonged mechanical ventilation in Guillain–Barré Syndrome. Neurocrit Care. 2017;26(1):6–13.CrossRefPubMed
34.
Shi M, Zhu J, Deng H. Clinical characteristics of intravenous injection of monosialotetrahexosyl ganglioside sodium-related Guillain–Barre syndrome. Front Neurol. 2019;10:225.CrossRefPubMedPubMedCentral
35.
Govoni V, Granieri E, Manconi M, Capone J, Casetta I. Is there a decrease in Guillain-Barré syndrome incidence after bovine ganglioside withdrawal in Italy? A population-based study in the Local Health District of Ferrara, Italy. J Neurol Sci. 2003;216(1):99–103.CrossRefPubMed
36.
Latov N, Koski CL, Walicke PA, Schönhöfer PS. Guillain–Barré syndrome and parenteral gangliosides. Lancet. 1991;338(8769):757.CrossRef
37.
Illa I, Ortiz N, Gallard E, et al. Acute axonal Guillain–Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann Neurol. 1995;38(2):218–24.CrossRefPubMed
38.
Funes SC, Chiari ME, Comín R, Irazoqui FJ, Nores GA. Experimental Guillain-Barre syndrome induced by immunization with gangliosides: keyhole limpet hemocyanin is required for disease triggering. Biochim Biophys Acta Mol Basis Dis. 2017;1863(6):1473–8.CrossRefPubMed
39.
Asthana P, Vong JS, Kumar G, et al. Dissecting the role of anti-ganglioside antibodies in Guillain–Barré syndrome: an animal model approach. Mol Neurobiol. 2016;53(7):4981–91.CrossRefPubMed
40.
Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain–Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol. 2001;49(6):712–20.CrossRefPubMed
Metadata
Title
Risk Factors for Mechanical Ventilation in Patients with Guillain–Barré Syndrome
Authors
Yanwei Cheng
Kangding Liu
Chunrong Li
Weiwei Zhang
Xiujuan Wu
Shaokuan Fang
Publication date
25-03-2022
Publisher
Springer US
Published in
Neurocritical Care / Issue 1/2022
Print ISSN: 1541-6933
Electronic ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-022-01457-8

Other articles of this Issue 1/2022

Neurocritical Care 1/2022 Go to the issue

Original work

Left Ventricular Function in the Initial Period After Severe Traumatic Brain Injury in Swine

Original work

Cerebral Microdialysis-Based Interventions Targeting Delayed Cerebral Ischemia Following Aneurysmal Subarachnoid Hemorrhage

Original work

Neurological Prognostication After Hypoglycemic Coma: Role of Clinical and EEG Findings

Original work

Safety and Efficacy of Vinpocetine as a Neuroprotective Agent in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis

Original work

Cerebral Blood Flow and Oxygen Delivery in Aneurysmal Subarachnoid Hemorrhage: Relation to Neurointensive Care Targets

Ethical Matters

Ethics Priorities of the Curing Coma Campaign: An Empirical Survey